Entasis Theraputics has initiated its Phase 1 clinical study of ETX2514 to evaluate the safety, tolerability and pharmacokinetics of ETX2514 in healthy volunteers.

Entasis’ next-generation beta-lactamase inhibitor, ETX2514 with a novel mode-of-action and expanded spectrum of antimicrobial activity is initially being developed in combination with sulbactam, a beta-lactam with activity against Acinetobacter baumannii.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The combination, ETX2514SUL, is a novel, potent antibiotic intended to target serious A. baumannii infections.

Entasis Therapeutics chief medical officer Robin Isaacs said: “We are very enthusiastic about the initiation of this clinical study, which will begin to establish the safety, tolerability and administration profile of ETX2514 in the clinic.

“This study builds on our extensive research in preclinical infection models, which indicate that the administration of sulbactam in combination with ETX2514 holds great promise against drug-resistant A. baumannii infections.”

See Also:

Entasis president and CEO Manos Perros said: “We strongly believe that ETX2514SUL could address a significant and increasing unmet medical need in patients with severe A. baumannii infections that are frequently resistant to modern antibiotics.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"The successful launch of this clinical study is a significant milestone for Entasis and represents a meaningful step forward in bringing ETX2514SUL to the patients who need it."

"The successful launch of this clinical study is a significant milestone for Entasis and represents a meaningful step forward in bringing ETX2514SUL to the patients who need it.”

The Phase I trial is a double-blind, randomised, placebo-controlled study of ETX2514 in healthy subjects.

It is intended to evaluate the safety, tolerability, and pharmacokinetics of ETX2514 alone and in combination with sulbactam.

The study is being conducted in Australia and is expected to be completed in the first half of 2017. 

Image: An SEM depicting clusters of A. baumannii bacteria. Photo: courtesy of Janice Carr.